



Sandwich Enzyme Immunoassay Kit Lixisenatide

Catalog No : **SEK 0130-02**

Background :

Lixisenatide, under development by sanofi-aventis, is a novel human glucagon-like peptide-1 receptor (GLP-1R) agonist for the treatment of type 2 diabetes mellitus (T2DM; non-insulin dependent diabetes). The structure of lixisenatide, based on **exendin-4(1-39)** modified, is able to withstand physiological degradation by dipeptidyl peptidase IV. In vitro, lixisenatide bound to human GLP-1R with a greater affinity than native human GLP-1 (7-36 amide). In various in vitro and in vivo models of T2DM, lixisenatide improved glycemic measures and demonstrated promising pancreatic beta-cell-preserving actions. In patients with T2DM, subcutaneously administered lixisenatide displayed linear pharmacokinetics.

Kit application: SEK Lixisenatide is a 96 wells sandwich immunoassay Kit. It can apply for the analysis of lixisenatide in serum, plasma, or tissue extracts in pharmacokinetics, peptide delivery study and other purposes.

This kit is for research use only.

Application Note : Room Temperature, 4-5 hours assay, 50ul sample size

Storage : 2 – 5 ° C

Detection Method : Colorimetric

Range : 0.13 - 100ng / ml

ED₂₀ : 0.98 ng/ml

ED₈₀ : 55.7 ng/ml


Specificity :

Lixisenatide

100%

Exendin-4 (1-39)	80%
Exendin-3	0%
Glucagon	0%
GLP-1 (7-37)	0%
GLP-1 (7-36)amide	0%

Typical Data



These standard curve is provided for demonstration only. A standard curve should be generated for each set of samples assayed.